Wednesday, June 10, 2009
Elizabeth Laur, firstname.lastname@example.org
+1 414-276-2145 (MDS Secretariat)
MDS 13th International Congress Press Room (June 7-11):
Le Palais des Congres de Paris,
Room 212/213, Level 2, Hall Maillot, TEL: +33 (0)1 40 68 63 74
Preliminary Findings Show that Parkinson's Disease Dementia and Lewy Bodies Patients Benefit from Memantine
PARIS - Researchers found that dementia with Lewy bodies (DLB) and dementia associated with Parkinson's disease significantly benefitted from memantine. This new research was presented at The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders.
Parkinson's disease dementia (PDD) refers to dementia that develops at least two years after the diagnosis of Parkinson's disease. Dementia with Lewy Bodies (DLB) is a progressive brain disease and the second leading cause of degenerative dementia in the elderly. Lewy body dementia exists either in pure form, or in conjunction with other brain changes, including those typically seen in Alzheimer's disease and Parkinson's disease.
This study, led by Dag Aarsland, MD, PhD, of the Norwegian Centre for Movement Disorders in Norway, conducted a double-blind placebo-controlled multicentre trial of memantine in patients with PDD and DLB in the UK and Scandinavia. Of the 56 patients who completed the study, a significant difference was found on the Clinical Global Impression of Change (CGIC) at week 24. The difference in the Mini Mental State Examination (MMSE) score was also 1.9 in favor of memantine.
The results of this study found that patients benefited from the drug, memantine. Future large-scale studies are needed to confirm these preliminary findings.
Meeting attendees are gathered to learn the latest research findings and state-of-the-art treatment options for Movement Disorders, including Parkinson's disease. More than 3,900 physicians and medical professionals from 90 countries will be able to view over 1,700 scientific abstracts submitted by clinicians from around the world.
The Movement Disorder Society, an international society of over 3,000 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about the Movement Disorder Society, visit www.movementdisorders.org.